CAR-T Therapy Trials for Multiple Myeloma Face FDA Scrutiny After Early Deaths

Boston, MA – The Food and Drug Administration (FDA) has raised concerns about early deaths in clinical trials for CAR-T cell therapies in multiple myeloma patients. The trials in question involve Johnson & Johnson’s Carvykti and Legend Biotech’s Carvykti, as well as Bristol Myers Squibb’s Abecma. CAR-T cell therapies have shown promise in treating certain types of cancer by genetically modifying a patient’s own immune cells to attack cancer cells. However, the FDA is now …

Read more

“Infection” Named Primary Cause of Nonrelapse Death in CAR T Therapy Study

LOS ANGELES, California – A recent study has revealed that infection is the leading cause of nonrelapse death among patients undergoing CAR T cell therapy for cancer. CAR T cell therapy is a type of immunotherapy that involves reprogramming a patient’s T cells to target cancer cells. The research, conducted by a team at the University of California, Los Angeles, examined the factors contributing to nonrelapse mortality in patients undergoing this innovative treatment. The study, …

Read more